Ask The Board

  1. What Is Your Opinion On Smaller Rare Disease Companies Being Acquired And Big Pharma’s Ability To Be Patient-Centric With These Populations?
    7/5/2018

    See the answer from John Crowley, the chairman & CEO of Amicus Therapeutics, a global biotechnology company focused on developing and delivering medicines for people living with rare, devastating diseases.

  2. When First Becoming A CEO, What Did You Soon Discover About Yourself As Being A Skill Gap, And How Did You Go About Filling It?
    7/5/2018

    See the answer from Julia Owens, Ph.D., president, CEO, and cofounder of Millendo Therapeutics, a company focused on endocrine drug development.

  3. Clinical Trials Continue To Increase In Complexity And Collect More Data. What Should Sponsors Do To Reduce The Costs Of Clinical Trials?
    6/1/2018

    See the answer from Mary Rose Keller, VP clinical operations at Tocagen who has 30+ years of industry experience in clinical development strategy and execution of global Phase 1 to 4 clinical trials for drug, biologic, and diagnostic products.

  4. Is There A Rise In Activist Investor Activity, And If So, What Is Driving It?
    6/1/2018

    See the answer from Dennis Purcell, a founder and senior advisor of Aisling Capital who has completed over 200 transactions and supervised over $15 billion life science industry financing and advisory assignments.

  5. What Does Every Biopharmaceutical Executive Need To Know About California’s New Drug Pricing Transparency Law, And How Likely Is This To Spread To Other States And Why?
    6/1/2018

    See the answer from Tom DiLenge, president, advocacy, law & public policy division for BIO. Prior to joining BIO, Tom held senior roles at the House Homeland Security and Energy and Commerce Committees.

  6. Is There Any Form Of Drug-Pricing Legislation You Could Get Behind, And, If So, What Would It Look Like?
    5/2/2018

    See the answer from Ron Cohen, M.D., president, CEO, and founder of Acorda Therapeutics, a public biotechnology company developing therapies for spinal cord injury, MS, and other nervous-system disorders.

  7. Knowing How Many Companies Use Various Social Media Outlets For Communications, What Impact Does The Recent Cambridge Analytica And Facebook Scandal Have On Our Company And Our Industry As A Whole?
    5/2/2018

    See the answer from Craig Lipset, head of clinical innovation within worldwide R&D at Pfizer.

  8. Why Are We Seeing Fewer Companies Willing To Make Older Generic Drugs, And What Can Be Done To Fix This Problem?
    4/6/2018

    See the answer from John LaMattina, Ph.D., the former senior VP at Pfizer, Inc. and president of Pfizer Global R&D.

  9. What Advice Do You Have For People Starting A Biopharma Company?
    4/6/2018

    See the answer from Francois Nader, MD, MBA, chairman of Acceleron Pharma and the former CEO of NPS Pharma.

  10. Any Suggestions For How To Work With Public-Sector Customers?
    4/6/2018

    See the answer from Jeff Berkowitz, a 25 year industry veteran, who has served in senior executive roles across the healthcare continuum with the likes of Schering-Plough, Merck, the Walgreens Boots Alliance and UnitedHealth Group.